Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Edwards Lifesciences (EW) Misses Q4 EPS by 4c, Beats on Revenue; Offers Q1 Guidance
February 10, 2026 4:16 PM ESTEdwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.58, $0.04 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $1.57 billion versus the consensus estimate of $1.55 billion.
GUIDANCE:
Edwards Lifesciences sees Q1 2026 EPS of $0.70-$0.76, versus the consensus of $0.69.... More
